Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Impact of Concomitant Antiemetics and Dopamine Agonists on Nausea and Vomiting
Objective: Analyze effect of concomitant antiemetics and dopamine agonists (DA) on nausea and vomiting (N/V) in patients receiving apomorphine sublingual film (APL-130277; APL) for on-demand…A monocentric experience of Apomorphine pump follow-up on PD patients: The Optipump Cohort
Objective: The goal of this study is to describe the factors that may have an impact on Continuous Subcutaneous Apomorphine Infusion (CSAI) therapy initiation and…Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Impact on Impulse Control Disorders
Objective: Evaluate effect of apomorphine sublingual film (APL-130277; APL) on impulse control disorders (ICD) in patients with Parkinson’s disease (PD) and “OFF” episodes. Background: In…Apomorphine as a Diagnostic tool to Identify Levodopa Responsive Atypical Parkinsonism
Objective: To assess the efficacy of apomorphine in identification of levodopa responsive atypical parkinsonism. Background: Management of atypical parkinsonism is a challenge. Most of these…A Long-Term Safety, Tolerability, and Efficacy Study of Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Interim Results
Objective: Evaluate the long-term safety (LTS), tolerability, and efficacy of apomorphine sublingual film (APL-130277; APL) for on-demand treatment of “OFF” episodes in patients with Parkinson’s…Reduction of OFF time with apomorphine infusion during hours of pump use: Analysis from a Phase III, open-label study
Objective: Evaluate the efficacy of apomorphine (APO) infusion in reducing OFF time during the hours of pump use in PD patients with motor fluctuations inadequately…Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Impact on Dyskinesia
Objective: Assess impact of apomorphine sublingual film (APL-130277; APL) on time spent with and functional impact of dyskinesia among patients with Parkinson’s disease (PD) and…A Long-Term Safety, Tolerability, and Efficacy Study of Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in De Novo vs Rollover Patients With Parkinson’s Disease: Interim Results
Objective: Evaluate long-term safety (LTS), tolerability, and efficacy of apomorphine sublingual film (APL-130277; APL) for on-demand treatment of “OFF” episodes in de novo (DN) vs…Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Effect on MDS-UPDRS Part III Subdomains
Objective: Evaluate effect of apomorphine sublingual film (APL-130277; APL) as an on-demand treatment of “OFF” episodes in patients with Parkinson’s disease (PD) on MDS-UPDRS Part…Dose Optimization of Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients with Parkinson’s Disease: Clinical and Exposure Response Findings
Objective: Evaluate if dose optimization (DO) of apomorphine sublingual film (APL-130277; APL) can achieve improved FULL “ON” response in patients with Parkinson’s disease (PD) and…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 13
- Next Page »